Back to News
Market Impact: 0.45
BioNTech's Gotistobart Nearly Doubles Median Overall Survival In Previously Treated Squamous NSCLC
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
BioNTech and OncoC4 reported updated Stage 1 PRESERVE-003 Phase 3 data showing gotistobart (BNT316/ONC-392) nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated patients. The survival result is a materially positive clinical signal for the companies' oncology program and could support further development and commercialization prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.68
Ticker Sentiment
BNTX0.82
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns
- Microsoft's Big Bets on AI Start to Pay Off